TY - JOUR
T1 - Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice?
AU - Chen, Yun
AU - Colonna, Marco
N1 - Funding Information:
Author contributions: Y. Chen and M. Colonna wrote the manuscript. Disclosures: M. Colonna reported grants from NIH during the conduct of the study and received research support from Alec-tor, Amgen, Ono, and Pfizer; in addition, M. Colonna is a scientific advisory board member of Vigil and NGMBio, is a consultant for Cell Signaling Technologies, and has a patent to TREM2 pending. No other disclosures were reported.
Funding Information:
This work was supported by the National Institutes of Health (grants RF1 AG051485, R21 AG059176, and RF1 AG059082 to M. Colonna).
Publisher Copyright:
© 2021 Chen and Colonna. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
PY - 2021/7/22
Y1 - 2021/7/22
N2 - Alzheimer’s disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated microglia (DAM); additional reactive microglial populations have been reported in other models of neurodegeneration and neuroinflammation. We review all of these microglial signatures, highlighting four fundamental patterns: DAM, IFN–microglia, MHC-II microglia, and proliferating microglia. We propose that all reported microglia populations are either just one or a combination, depending on the clustering strategy applied and the disease model. We further review single-nucleus RNA sequencing (snRNA-seq) data from human AD specimens and discuss reasons for parallels and discrepancies between human and mouse transcriptional profiles. Finally, we outline future directions for delineating the microglial impact in AD pathogenesis.
AB - Alzheimer’s disease (AD) is characterized by extracellular aggregates of amyloid β peptides, intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of microglia. Because variants of genes expressed in microglia correlate with AD risk, microglial response to pathology plausibly impacts disease course. In mouse AD models, single-cell RNA sequencing (scRNA-seq) analyses delineated this response as progressive conversion of homeostatic microglia into disease-associated microglia (DAM); additional reactive microglial populations have been reported in other models of neurodegeneration and neuroinflammation. We review all of these microglial signatures, highlighting four fundamental patterns: DAM, IFN–microglia, MHC-II microglia, and proliferating microglia. We propose that all reported microglia populations are either just one or a combination, depending on the clustering strategy applied and the disease model. We further review single-nucleus RNA sequencing (snRNA-seq) data from human AD specimens and discuss reasons for parallels and discrepancies between human and mouse transcriptional profiles. Finally, we outline future directions for delineating the microglial impact in AD pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85111517284&partnerID=8YFLogxK
U2 - 10.1084/jem.20202717
DO - 10.1084/jem.20202717
M3 - Review article
C2 - 34292312
AN - SCOPUS:85111517284
SN - 0022-1007
VL - 218
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 9
M1 - e20202717
ER -